22.15

1.00% 0.22

After Hours: 22.42 0.27 +1.22%

Definium Therapeutics Inc (DFTX)

Overview News Price History Discussions Forecast

Definium Therapeutics Inc stock is traded at $22.15, with a volume of 1.50M. It is up +1.00% in the last 24 hours and up +22.65% over the past month. Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Previous Close:

$21.93

Open:

$22

24h Volume:

1.50M

Relative Volume:

0.96

Market Cap:

$2.21B

Revenue:

Net Income/Loss:

$-183.79M

P/E Ratio:

-10.71

EPS:

-2.0691

Net Cash Flow:

$-131.84M

1W Performance:

+5.38%

1M Performance:

+22.65%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$21.46

$22.20

1-Week Range:

$20.41

$23.04

52-Week Range:

$14.62

$23.04

Definium Therapeutics Inc Stock (DFTX) Company Profile

Name

Definium Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

212-220-6633

Address

ONE WORLD TRADE CENTER, NEW YORK

Employee

106

Twitter

Next Earnings Date

Latest SEC Filings

DFTX's Discussions on Twitter

Compare DFTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DFTX Definium Therapeutics Inc	22.15	2.19B	0	-183.79M	-131.84M	-2.0691
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Piper Sandler	Overweight
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-30-26	Initiated	Jefferies	Buy
Oct-13-25	Initiated	Needham	Buy
Aug-04-25	Resumed	Oppenheimer	Outperform
Jan-28-25	Initiated	Evercore ISI	Outperform
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Jul-24-24	Initiated	ROTH MKM	Buy
May-29-24	Initiated	Robert W. Baird	Outperform
Apr-15-24	Initiated	Leerink Partners	Outperform
Dec-05-23	Initiated	Canaccord Genuity	Buy
Dec-09-22	Resumed	ROTH Capital	Buy
Nov-16-22	Initiated	RBC Capital Mkts	Outperform
Aug-26-22	Initiated	Oppenheimer	Outperform
Aug-10-22	Initiated	Cantor Fitzgerald	Overweight
May-04-22	Initiated	ROTH Capital	Buy
Jun-28-21	Initiated	Maxim Group	Buy

View All

Definium Therapeutics Inc Stock (DFTX) Latest News

Apr 15, 2026

Definium Therapeutics (DFTX) Short Interest & Short Float | Updated Apr 2026 - MarketBeat

Apr 15, 2026

Definium Therapeutics stock hits 52-week high at 21.99 USD By Investing.com - Investing.com UK

Apr 10, 2026

Piper Sandler Initiates Definium Therapeutics at Overweight - marketscreener.com

Apr 10, 2026

Piper Sandler initiates Definium stock with Overweight rating By Investing.com - Investing.com South Africa

Apr 10, 2026

Piper Sandler initiates Definium stock with Overweight rating - Investing.com UK

Apr 10, 2026

Apr 09, 2026

Investment bank Piper Sandler announced the official initiation of coverage on biopharmaceutical company Definium Therapeutics Inc, assigning it an "Overweight" rating. - Bitget

Apr 09, 2026

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - marketscreener.com

Apr 09, 2026

Apr 08, 2026